Zoeken
Algemene medische oncologie

Klinische studies melanoom en andere huidtumoren

Op deze pagina

Planned

EIK1001-006

A Multicenter, Randomized, Double-Blind, Active Comparator-Controlled, Adaptive Phase 2/3 Study to Evaluate the Safety and Efficacy of EIK1001 and Pembrolizumab Versus Placebo and Pembrolizumab as First-Line Therapy in Participants with Advanced Melanoma

PRISM-MEL-301 - IMC-F106C-301

A Phase 3 Randomized, Controlled Study of IMC-F106C Plus Nivolumab Versus Nivolumab Regimens in HLA-A*02: 01-Positive Participants With Previously Untreated Advanced Melanoma (PRISM-MEL-301)

Ongoing

BP44956

A Dose-escalation Study of RO7567132 as Single Agent and in Combination With Atezolizumab in Participants With Advanced Solid Tumors.

HERTHENA - U31402-277

HERTHENA-PanTumor01 (U31402-277): A Phase 2, Multicenter, Open-label, Proof of Concept Study of Patritumab Deruxtecan (HER3-DXd) in Locally Advanced or Metastatic Solid Tumors

IMCGP100-203

Phase 2/3 Randomized Study of Tebentafusp as Monotherapy and in Combination with Pembrolizumab Versus Investigator’s Choice in HLA-A*02:01-positive Participants with Previously Treated Advanced Melanoma (TEBE-AM)

REGENERON - R2810-ONC-1788

A Randomized, Placebo-Controlled, Double-Blind Study of Adjuvant Cemiplimab Versus Placebo After Surgery and Radiation Therapy in Patients With High Risk Cutaneous Squamous Cell Carcinoma

  • Principal investigator : Prof. Dr. O. Bechter
  • Sponsor : Regeneron Pharmaceuticals
  • More information : NCT03969004
  • Indication : 
  • Internal reference number : s62852

V940-001

A Phase 3 Randomized, Double-blind, Placebo- and Active Comparator-Controlled Clinical study of Adjuvant V940 (mRNA-4157) Plus Pembrolizumab Versus Adjuvant Placebo Plus Pembrolizumab in Participants with High-risk Stage II-IV Melanoma

Closed

ARRAY CMEK162X2110

A Phase Ib/II, Multicenter, Open-label, Dose Escalation Study of LGX818 in Combination With MEK162 in Adult Patients With BRAF V600 - Dependent Advanced Solid Tumors

CA045-001

A Phase 3, Randomized, Open-label Study of NKTR-214 Combined With Nivolumab Versus Nivolumab in Participants With Previously Untreated Unresectable or Metastatic Melanoma

  • Principal investigator : Prof. Dr. O. Bechter
  • Sponsor : Bristol-Myers-Squibb
  • More information : NCT03635983
  • Indication : 
  • Internal reference number : s61873

CLXH254C12201

A phase II randomized, open-label, multi-arm combinations in previously treated unresectable or metastatic BRAFV600 or NRAS mutant Melanoma

COMBI V MEK116513

A Phase III, Randomised, Open-label Study Comparing the Combination of the BRAF Inhibitor, Dabrafenib and the MEK Inhibitor, Trametinib to the BRAF Inhibitor Vemurafenib in Subjects With Unresectable (Stage IIIc) or Metastatic (Stage IV) BRAF V600E/K Mutation Positive Cutaneous Melanoma

IMBRELLA B BO40729

An Open Label, Multicenter Extension Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study

IMSPIRE170 CO39722

A Phase III, Open-Label, Multicenter, Two Arm, Randomized Study to Investigate the Efficacy and Safety of Cobimetinib Plus Atezolizumab Versus Pembrolizumab in Patients With Previously Untreated Advanced BRAF V600 Wild-Type Melanoma

INITIUM UV1-202

Efficacy and Safety of UV1 Vaccination in Combination With Nivolumab and Ipilimumab as First Line Treatment of Patients With Unresectable or Metastatic Melanoma

KEYNOTE-006 MK3475-006

A multicenter, randomized, controlled, two-arm, phase III study to evaluate the safety and efficacy of MK-3475 compared to ipilimumab in patients with advanced melanoma

KEYNOTE-587 MK3475-587

A Multicenter, Open Label, Phase III Extension Trial to Study the Long-term Safety and Efficacy in Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab Trial

KEYNOTE-716 MK3475-716

Adjuvant Therapy With Pembrolizumab Versus Placebo in Resected High-risk Stage II Melanoma: A Randomized, Double-blind Phase 3 Study

KEYVIBE - MK7684A-010

A Phase 3, Randomized, Double-blind, Active-Comparator-Controlled clinical Study of Adjuvant MK-7684A (Vibostolimab with Pembrolizumab) Versus Adjuvant Pembrolizumab in Participants with High-risk Stage II-IV Melanoma (KEYVIBE-010)

MONETTE - D533AC00001

A Randomised, Open-Label, Phase 2 Study of Ceralasertib and  Ceralasertib plus Durvalumab in Patients with Unresectable or Advanced Melanoma and  Primary or Secondary Resistance to PD-(L)1 inhibition

MERKLIN2 4SC-202-3-2018

A phase II, open label, multicenter study to investigate the efficacy and safety of domatinostat in combination with avelumab in patients with advanced, unresectable Merkel-Cell Carcinoma

1211_NOUS-PEV-01

An Open-Label, Multicenter, Non-Randomized, Dose confimiation and cohort Expansion Phase lb Study to Evaiuate the Safety, Tolerability, and Anti-Tumor Activity of Nous-PEV, a personalized genetic vaccine composed of a one GAd2O-PEV priming and 3 MVA-PEV boosting administration) with Pembroiizumab as per SoC PD1 inhibitor, in Patients with Stage lii (unresectable) / Stage IV Melanoma cancer or Stage IV NSCLC

  • Principal investigator : Prof. Dr. O. Bechter
  • Sponsor : Pharm-Olam LLC Pharm-Olam LLC
  • More information : NCT04990479
  • Indication : 
  • Internal reference number : s64578

R2810-ONC-1620

A Phase 2 Study of REGN2810, a Fully Human Monoclonal Antibody to Programmed Death-1, in Patients With Advanced Basal Cell Carcinoma Who Experienced Progression of Disease on Hedgehog Pathway Inhibitor Therapy, or Were Intolerant of Prior Hedgehog Pathway Inhibitor Therapy

TRILOGY CO39262

A phase III, double-blinded, randomized, placebo-controlled study of atezolizumab plus cimetinib and vemurafenib versus placebo plus cobimetinib and vemurafenib in previously untreated BRAF V600 mutation-positive patients with unresectable locally advanced or metastatic melanoma

Laatste aanpassing: 23 oktober 2024